Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer von Kojima, Takashi, Shah, Manish A., Muro, Kei, Francois, Eric, Adenis, Antoine, Hsu, Chih-Hung, Doi, Toshihiko, Moriwaki, Toshikazu, Kim, Sung-Bae, Lee, Se-Hoon, Bennouna, Jaafar, Kato, Ken, Shen, Lin, Enzinger, Peter, Qin, Shu-Kui, Ferreira, Paula, Chen, Jia, Girotto, Gustavo, de la Fouchardiere, Christelle, Senellart, Helene, Al-Rajabi, Raed, Lordick, Florian, Wang, Ruixue, Suryawanshi, Shailaja, Bhagia, Pooja, Kang, S. Peter, Metges, Jean-Philippe

Volltext

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade von Le, Dung T., Durham, Jennifer N., Smith, Kellie N., Wang, Hao, Bartlett, Bjarne R., Aulakh, Laveet K., Lu, Steve, Kemberling, Holly, Wilt, Cara, Luber, Brandon S., Wong, Fay, Azad, Nilofer S., Rucki, Agnieszka A., Laheru, Dan, Donehower, Ross, Zaheer, Atif, Fisher, George A., Crocenzi, Todd S., Lee, James J., Greten, Tim F., Duffy, Austin G., Ciombor, Kristen K., Eyring, Aleksandra D., Lam, Bao H., Joe, Andrew, Kang, S. Peter, Holdhoff, Matthias, Danilova, Ludmila, Cope, Leslie, Meyer, Christian, Zhou, Shibin, Goldberg, Richard M., Armstrong, Deborah K., Bever, Katherine M., Fader, Amanda N., Taube, Janis, Housseau, Franck, Spetzler, David, Xiao, Nianqing, Pardoll, Drew M., Papadopoulos, Nickolas, Kinzler, Kenneth W., Eshleman, James R., Vogelstein, Bert, Anders, Robert A., Diaz, Luis A.

Volltext

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma von Daud, Adil I, Wolchok, Jedd D, Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S, Ribas, Antoni, Hodi, F Stephen, Joshua, Anthony M, Kefford, Richard, Hersey, Peter, Joseph, Richard, Gangadhar, Tara C, Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K, Li, Xiaoyun Nicole, Emancipator, Kenneth, Dolled-Filhart, Marisa, Kang, S Peter, Ebbinghaus, Scot, Hamid, Omid

Volltext

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma von Hamid, Omid, Robert, Caroline, Daud, Adil, Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Wolchok, Jedd D, Hersey, Peter, Joseph, Richard W, Weber, Jeffrey S, Dronca, Roxana, Gangadhar, Tara C, Patnaik, Amita, Zarour, Hassane, Joshua, Anthony M, Gergich, Kevin, Elassaiss-Schaap, Jeroen, Algazi, Alain, Mateus, Christine, Boasberg, Peter, Tumeh, Paul C, Chmielowski, Bartosz, Ebbinghaus, Scot W, Li, Xiaoyun Nicole, Kang, S. Peter, Ribas, Antoni

Volltext

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade von Ayers, Mark, Lunceford, Jared, Nebozhyn, Michael, Murphy, Erin, Loboda, Andrey, Kaufman, David R, Albright, Andrew, Cheng, Jonathan D, Kang, S Peter, Shankaran, Veena, Piha-Paul, Sarina A, Yearley, Jennifer, Seiwert, Tanguy Y, Ribas, Antoni, McClanahan, Terrill K

Volltext

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors von Patnaik, Amita, Kang, S Peter, Rasco, Drew, Papadopoulos, Kyriakos P, Elassaiss-Schaap, Jeroen, Beeram, Muralidhar, Drengler, Ronald, Chen, Cong, Smith, Lon, Espino, Guillermo, Gergich, Kevin, Delgado, Liliana, Daud, Adil, Lindia, Jill A, Li, Xiaoyun Nicole, Pierce, Robert H, Yearley, Jennifer H, Wu, Dianna, Laterza, Omar, Lehnert, Manfred, Iannone, Robert, Tolcher, Anthony W

Volltext

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab von Hodi, F Stephen, Hwu, Wen-Jen, Kefford, Richard, Weber, Jeffrey S, Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C, Joshua, Anthony M, Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S Peter, Ebbinghaus, Scot, Perrone, Andrea, Wolchok, Jedd D

Volltext

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma? von Wang, Meihua, Chen, Cong, Jemielita, Thomas, Anderson, James, Li, Xiaoyun Nicole, Hu, Chen, Kang, S Peter, Ibrahim, Nageatte, Ebbinghaus, Scot

Volltext

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma von Ribas, Antoni, Hamid, Omid, Daud, Adil, Hodi, F. Stephen, Wolchok, Jedd D, Kefford, Richard, Joshua, Anthony M, Patnaik, Amita, Hwu, Wen-Jen, Weber, Jeffrey S, Gangadhar, Tara C, Hersey, Peter, Dronca, Roxana, Joseph, Richard W, Zarour, Hassane, Chmielowski, Bartosz, Lawrence, Donald P, Algazi, Alain, Rizvi, Naiyer A, Hoffner, Brianna, Mateus, Christine, Gergich, Kevin, Lindia, Jill A, Giannotti, Maxine, Li, Xiaoyun Nicole, Ebbinghaus, Scot, Kang, S. Peter, Robert, Caroline

Volltext

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab von Joseph, Richard W, Elassaiss-Schaap, Jeroen, Kefford, Richard, Hwu, Wen-Jen, Wolchok, Jedd D, Joshua, Anthony M, Ribas, Antoni, Hodi, F Stephen, Hamid, Omid, Robert, Caroline, Daud, Adil, Dronca, Roxana, Hersey, Peter, Weber, Jeffrey S, Patnaik, Amita, de Alwis, Dinesh P, Perrone, Andrea, Zhang, Jin, Kang, S Peter, Ebbinghaus, Scot, Anderson, Keaven M, Gangadhar, Tara C

Volltext

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial von Robert, Caroline, Prof, Ribas, Antoni, Prof, Wolchok, Jedd D, Prof, Hodi, F Stephen, MD, Hamid, Omid, MD, Kefford, Richard, Prof, Weber, Jeffrey S, Prof, Joshua, Anthony M, PhD, Hwu, Wen-Jen, Prof, Gangadhar, Tara C, MD, Patnaik, Amita, MD, Dronca, Roxana, MD, Zarour, Hassane, Prof, Joseph, Richard W, MD, Boasberg, Peter, MD, Chmielowski, Bartosz, MD, Mateus, Christine, MD, Postow, Michael A, MD, Gergich, Kevin, MA, Elassaiss-Schaap, Jeroen, PhD, Li, Xiaoyun Nicole, PhD, Iannone, Robert, MD, Ebbinghaus, Scot W, MD, Kang, S Peter, MD, Daud, Adil, Prof

Volltext

Pembrolizumab von Khoja, Leila, Butler, Marcus O, Kang, S Peter, Ebbinghaus, Scot, Joshua, Anthony M

Volltext

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma von Schadendorf, Dirk, Dummer, Reinhard, Hauschild, Axel, Robert, Caroline, Hamid, Omid, Daud, Adil, van den Eertwegh, Alfons, Cranmer, Lee, O'Day, Steven, Puzanov, Igor, Schachter, Jacob, Blank, Christian, Salama, April, Loquai, Carmen, Mehnert, Janice M, Hille, Darcy, Ebbinghaus, Scot, Kang, S. Peter, Zhou, Wei, Ribas, Antoni

Volltext

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors von ELEZ, María Elena, TABERNERO, Josep, SZYLDERGEMAJN, Sergio, RATAIN, Mark J, GEARY, David, MACARULLA, Teresa, KANG, S. Peter, KAHATT, Carmen, PITA, Arturo Soto-Matos, TERUEL, Carlos Fernandez, SIGUERO, Mariano, CULLELL-YOUNG, Martin

Volltext

Testing monotherapy and combination therapy in one trial with biomarker consideration von Sun, Linda Z., Kang, S. Peter, Chen, Cong

Volltext

A Blueprint to Advance Colorectal Cancer Immunotherapies von Le, Dung T, Hubbard-Lucey, Vanessa M, Morse, Michael A, Heery, Christopher R, Dwyer, Andrea, Marsilje, Thomas H, Brodsky, Arthur N, Chan, Emily, Deming, Dustin A, Diaz, Jr, Luis A, Fridman, Wolf H, Goldberg, Richard M, Hamilton, Stanley R, Housseau, Franck, Jaffee, Elizabeth M, Kang, S Peter, Krishnamurthi, Smitha S, Lieu, Christopher H, Messersmith, Wells, Sears, Cynthia L, Segal, Neil H, Yang, Arvin, Moss, Rebecca A, Cha, Edward, O'Donnell-Tormey, Jill, Roach, Nancy, Davis, Anjelica Q, McAbee, Keavy, Worrall, Sharyn, Benson, Al B

Volltext

P-275First-line pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma: randomized,... von Luis, Diaz, Dung, Le, Takayuki, Yoshino, Thierry, Andre, Johanna, Bendell, Minori, Koshiji, Yinghua, Zhang, Peter, Kang S, Bao, Lam, Dirk, Jaeger

Volltext

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study von Shah, Manish A., Adenis, Antoine, Enzinger, Peter C., Kojima, Takashi, Muro, Kei, Bennouna, Jaafar, Francois, Eric, Hsu, Chih-Hung, Moriwaki, Toshikazu, Kim, Sung-Bae, Lee, Se-Hoon, Kato, Ken, Shen, Lin, Qin, Shukui, Ferreira, Paula, Wang, Ruixue, Bhagia, Pooja, Kang, S. Peter, Metges, Jean-Philippe, Doi, Toshihiko

Volltext

Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells von You, Fanglei, Roberts, Lisa A, Kang, S Peter, Nunes, Raquel A, Dias, Cinara, Iglehart, J Dirk, Solomon, Natalie A, Friedman, Paula N, Harris, Lyndsay N

Volltext

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study von Kojima, Takashi, Muro, Kei, Francois, Eric, Hsu, Chih-Hung, Moriwaki, Toshikazu, Kim, Sung-Bae, Lee, Se-Hoon, Bennouna, Jaafar, Kato, Ken, Lin, Shen, Qin, Shi-Qui, Ferreira, Paula, Doi, Toshihiko, Adenis, Antoine, Enzinger, Peter C., Shah, Manish A., Wang, Ruixue, Bhagia, Pooja, Kang, S. Peter, Metges, Jean-Philippe

Volltext